Department of Chemistry, Seoul National University, Seoul, Republic of Korea.
Center for Genome Engineering, Institute for Basic Science, Seoul, Republic of Korea.
Nat Biotechnol. 2019 Apr;37(4):430-435. doi: 10.1038/s41587-019-0050-1. Epub 2019 Mar 4.
Adenine base editors enable efficient targeted adenine-to-guanine single nucleotide conversions to induce or correct point mutations in human cells, animals, and plants. Here we present a modified version of Digenome-seq, an in vitro method for identifying CRISPR (clustered regularly interspaced short palindromic repeats)-induced double-strand breaks using whole-genome sequencing, to assess genome-wide target specificity of adenine base editors. To produce double-strand breaks at sites containing inosines, the products of adenine deamination, we treat human genomic DNA with an adenine base editor 7.10 protein-guide RNA complex and either endonuclease V or a combination of human alkyladenine DNA glycosylase and endonuclease VIII in vitro. Digenome-seq detects adenine base editor off-target sites with a substitution frequency of 0.1% or more. We show that adenine base editor 7.10, the cytosine base editor BE3, and unmodified CRISPR-associated protein 9 (Cas9) often recognize different off-target sites, highlighting the need for independent assessments of their genome-wide specificities. Using targeted sequencing, we also show that use of preassembled adenine base editor ribonucleoproteins, modified guide RNAs, and Sniper/Cas9 (ref. ) reduces adenine base editor off-target activity in human cells.
腺嘌呤碱基编辑器能够高效地靶向腺嘌呤到鸟嘌呤的单核苷酸转换,从而在人类细胞、动物和植物中诱导或纠正点突变。在这里,我们介绍了一种改良的 Digenome-seq 方法,这是一种体外方法,用于使用全基因组测序来鉴定 CRISPR(成簇的、规律间隔的短回文重复序列)诱导的双链断裂,以评估腺嘌呤碱基编辑器的全基因组靶向特异性。为了在含有肌苷的位点(腺嘌呤脱氨酶的产物)产生双链断裂,我们用人腺嘌呤碱基编辑器 7.10 蛋白-向导 RNA 复合物和内切核酸酶 V 或人烷基腺嘌呤 DNA 糖基化酶和内切核酸酶 VIII 的混合物在体外处理人基因组 DNA。Digenome-seq 以 0.1%或更高的取代频率检测腺嘌呤碱基编辑器的脱靶位点。我们表明,腺嘌呤碱基编辑器 7.10、胞嘧啶碱基编辑器 BE3 和未经修饰的 CRISPR 相关蛋白 9(Cas9)通常识别不同的脱靶位点,这突出了需要独立评估它们的全基因组特异性。通过靶向测序,我们还表明,使用预组装的腺嘌呤碱基编辑器核糖核蛋白、修饰的向导 RNA 和 Sniper/Cas9(参考文献)可降低人细胞中腺嘌呤碱基编辑器的脱靶活性。